Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
ELVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.96 - $30.03
Previous CloseN/A
Volume37.78K
Average Volume (3M)203.33K
Market Cap
$1.03B
Enterprise Value$940.95M
Total Cash (Recent Filing)$124.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 08, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding49,004,425
10 Day Avg. Volume232,945
30 Day Avg. Volume203,331
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.03
Forecast
1Y Price Target
$38.00Price Target Upside80.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Enliven Therapeutics News
See All ELVN News
---
Bulls Say, Bears Say
Bulls Say
Financial PositionEnliven ended 2024 with ~$313.4M in cash and equivalents; this should support an operational runway extending into mid-2027, spanning multiple potentially impactful data readouts.
Market PotentialAn impressive launch of Scemblix in the early-line CML setting has positive readthrough to the opportunity for ELVN-001 if the data hold, as it supports the thesis that a highly efficacious and well tolerated treatment can gain significant use and achieve blockbuster status in CML.
Product EfficacyELVN-001 achieved a cumulative major molecular response (MMR) rate of 44% by 24 weeks and showed responses in patients with prior exposure to asciminib and/or who were TKI-resistant.
Bears Say
Investor SentimentShort Interest (% Float) 23.4%
Market ChallengesThe HER2 program is in a competitive space with high development costs, and the market currently views it as a free option, indicating potential financial challenges.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $15.96 and its highest was $30.03 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $1.03B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 38 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Mar 13, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.515 by $0.055.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.5.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 49,004,425 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.515. Following the earnings report the stock price went up 2.218%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
---
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (80.35% Upside)
$38.00 (80.35% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 206.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.78%
12-Months-Change
Fundamentals
Return on Equity
-32.04%
Trailing 12-Months
Asset Growth
19.82%
Trailing 12-Months
Company Description
Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
---
ELVN Stock 12 Month Forecast
Average Price Target
$38.00
▲(80.35% Upside)
Technical Analysis
Best Analysts Covering ELVN
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+21.29%
reiterated a buy rating 10 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +21.29% per trade.
---